PE20050880A1 - Proceso para reducir la cantidad de 14-hidroxicodeinona en una preparacion de clorhidrato de oxicodona - Google Patents

Proceso para reducir la cantidad de 14-hidroxicodeinona en una preparacion de clorhidrato de oxicodona

Info

Publication number
PE20050880A1
PE20050880A1 PE2005000361A PE2005000361A PE20050880A1 PE 20050880 A1 PE20050880 A1 PE 20050880A1 PE 2005000361 A PE2005000361 A PE 2005000361A PE 2005000361 A PE2005000361 A PE 2005000361A PE 20050880 A1 PE20050880 A1 PE 20050880A1
Authority
PE
Peru
Prior art keywords
oxycodone
hydroxycodeinone
composition
amount
hydrochloride
Prior art date
Application number
PE2005000361A
Other languages
English (en)
Spanish (es)
Inventor
Robert Chapman
Lonn S Rider
Qi Hong
Donald Kyle
Robert Kupper
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35124996&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20050880(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of PE20050880A1 publication Critical patent/PE20050880A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C07D489/04—Salts; Organic complexes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
PE2005000361A 2004-03-30 2005-03-29 Proceso para reducir la cantidad de 14-hidroxicodeinona en una preparacion de clorhidrato de oxicodona PE20050880A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US55749204P 2004-03-30 2004-03-30
US60153404P 2004-08-13 2004-08-13
US62007204P 2004-10-18 2004-10-18
US64862505P 2005-01-31 2005-01-31
US65177805P 2005-02-10 2005-02-10

Publications (1)

Publication Number Publication Date
PE20050880A1 true PE20050880A1 (es) 2005-11-16

Family

ID=35124996

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000361A PE20050880A1 (es) 2004-03-30 2005-03-29 Proceso para reducir la cantidad de 14-hidroxicodeinona en una preparacion de clorhidrato de oxicodona

Country Status (38)

Country Link
US (35) US7129248B2 (enExample)
EP (7) EP2316837B1 (enExample)
JP (8) JP4912294B2 (enExample)
KR (12) KR101200700B1 (enExample)
CN (5) CN101812065B (enExample)
AP (1) AP2232A (enExample)
AR (1) AR049012A1 (enExample)
AT (2) ATE501150T1 (enExample)
AU (2) AU2005230826C1 (enExample)
BR (1) BRPI0508758B8 (enExample)
CA (3) CA2774121C (enExample)
CR (2) CR8593A (enExample)
CY (5) CY1111487T1 (enExample)
DE (2) DE602005026786D1 (enExample)
DK (6) DK2319846T3 (enExample)
EA (1) EA013208B1 (enExample)
EC (1) ECSP066953A (enExample)
ES (6) ES2585576T3 (enExample)
FI (1) FI7843U1 (enExample)
HR (5) HRP20110425T4 (enExample)
HU (3) HUE029913T2 (enExample)
IL (8) IL178038A (enExample)
LT (2) LT2316837T (enExample)
MA (1) MA28492B1 (enExample)
ME (4) ME01299B (enExample)
MX (2) MX363228B (enExample)
MY (3) MY172063A (enExample)
NO (1) NO337669B1 (enExample)
NZ (3) NZ549430A (enExample)
PE (1) PE20050880A1 (enExample)
PL (5) PL2305683T3 (enExample)
PT (5) PT2319846T (enExample)
RS (5) RS53891B1 (enExample)
SG (3) SG170736A1 (enExample)
SI (5) SI2319846T1 (enExample)
TW (3) TWI483944B (enExample)
WO (1) WO2005097801A1 (enExample)
ZA (1) ZA200607181B (enExample)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE102005005446A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
PT1842533E (pt) * 2003-08-06 2013-05-17 Gruenenthal Gmbh Forma de dosagem protegida contra abuso
DE102004020220A1 (de) * 2004-04-22 2005-11-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE10361596A1 (de) * 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
TWI483944B (zh) * 2004-03-30 2015-05-11 Euro Celtique Sa 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
DE102004032049A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102004032103A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
GB0421149D0 (en) * 2004-09-23 2004-10-27 Johnson Matthey Plc Preparation of oxycodone
US20080152595A1 (en) * 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
DE102005005449A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
HRP20090387T1 (hr) 2005-03-04 2009-08-31 Euro-Celtique S.A. Postupak reduciranja alfa, beta nezasićenih ketona u opioidnim sastavima
US20070082845A1 (en) * 2005-07-15 2007-04-12 The Penn State Research Foundation Ferritin as a therapeutic target in abnormal cells
CN101346384B (zh) 2005-11-22 2012-07-04 控制化学品公司 用于降低羟考酮和其它组分中杂质迈克尔受体水平的方法
US20070117826A1 (en) * 2005-11-23 2007-05-24 Forest Laboratories, Inc. Pharmaceutical formulations comprising ibuprofen, oxycodone, and 14-hydroxycodeinone
WO2007103105A2 (en) * 2006-03-02 2007-09-13 Mallinckrodt Inc. Processes for preparing morphinan-6-one products with low levels of alpha, beta-unsaturated ketone compounds
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
CA2674915C (en) * 2006-10-17 2015-06-30 Penick Corporation Process for preparing oxymorphone
DK2073636T3 (da) * 2006-10-17 2012-11-19 Penick Corp Fremgangsmåde til fremstilling af oxymorphon
US20080125592A1 (en) * 2006-10-17 2008-05-29 Penick Corporation Process for preparing oxymorphone, naltrexone, and buprenorphine
WO2008070656A2 (en) * 2006-12-04 2008-06-12 Noramco, Inc Process for reducing impurities in oxycodone base
ES2393221T3 (es) * 2006-12-04 2012-12-19 Noramco, Inc. Procedimiento de preparación de oxicodona con niveles reducidos de 14-hidroxicodeinona
GB0624880D0 (en) * 2006-12-14 2007-01-24 Johnson Matthey Plc Improved method for making analgesics
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
JP2010522189A (ja) * 2007-03-23 2010-07-01 マリンクロッド・インコーポレイテッド オリパビンからのオキシモルホンの改善された調製
MX2009010931A (es) * 2007-04-16 2009-10-29 Mallinckrodt Inc Reduccion novedosa de opiaceos utilizando la reaccion de transferencia catalitica de hidrogeno.
CN102014877B (zh) 2008-01-25 2017-06-06 格吕伦塔尔有限公司 药物剂型
AU2009223061B2 (en) * 2008-03-11 2014-10-09 Depomed Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8372432B2 (en) * 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
PL2273983T3 (pl) 2008-05-09 2017-01-31 Grünenthal GmbH Sposób wytwarzania pośredniego preparatu proszkowego i końcowej stałej postaci dawkowania z zastosowaniem etapu zestalania rozpyłowego
US20110165248A1 (en) * 2008-09-18 2011-07-07 Meridith Lee Machonis Pharmaceutical dosage forms comprising poly(e-caprolactone)
CA2765971C (en) * 2009-07-22 2017-08-22 Gruenenthal Gmbh Hot-melt extruded controlled release dosage form
JP2012533585A (ja) 2009-07-22 2012-12-27 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 酸化感受性オピオイドのための不正使用防止剤形
EP2473195A4 (en) * 2009-08-31 2013-01-16 Depomed Inc PHARMACEUTICAL MAGNETIC RELEASE COMPOSITIONS FOR IMMEDIATE AND EXTENDED RELEASE OF ACETAMINOPHES
ES2569925T3 (es) 2009-09-30 2016-05-13 Acura Pharmaceuticals, Inc. Métodos y composiciones de disuasión del abuso
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
WO2011095314A2 (en) * 2010-02-03 2011-08-11 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of an extruder
EP2377866B1 (en) 2010-03-23 2014-02-26 Siegfried AG Preparation of low impurity opiates in a continuous flow reactor
BR112012028788A2 (pt) 2010-05-10 2016-07-19 Euro Celtique Sa fabricação de grânulos sem ativos
CN102946870A (zh) 2010-05-10 2013-02-27 欧洲凯尔特公司 包含氢吗啡酮和纳洛酮的药物组合物
JP5840201B2 (ja) 2010-05-10 2016-01-06 ユーロ−セルティーク エス．エイ． 活性剤を負荷した顆粒と追加の活性剤の組合せ
TWI471289B (zh) 2010-06-11 2015-02-01 Rhodes Technologies 使三級胺進行ｎ－脫烷反應之方法
AU2011263417B2 (en) 2010-06-11 2014-03-27 Rhodes Technologies Transition metal-catalyzed processes for the preparation of N-allyl compounds and use thereof
CA2804101C (en) 2010-07-02 2021-01-19 Johnson Matthey Public Limited Company Process for the synthesis and purification of oxycodone
US8912781B2 (en) * 2010-07-30 2014-12-16 Cirrus Logic, Inc. Integrated circuit switching power supply controller with selectable buck mode operation
NZ608865A (en) 2010-09-02 2015-03-27 Gruenenthal Chemie Tamper resistant dosage form comprising an anionic polymer
CA2808219C (en) 2010-09-02 2019-05-14 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt
US8658631B1 (en) 2011-05-17 2014-02-25 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
MX348491B (es) 2011-07-29 2017-06-15 Gruenenthal Gmbh Tableta a prueba de manipulacion que proporciona liberacion inmediata de fármaco.
PT2736497T (pt) 2011-07-29 2017-11-30 Gruenenthal Gmbh Comprimido resistente a adulteração proporcionando libertação imediata de fármaco
WO2013034273A1 (en) * 2011-09-05 2013-03-14 Siegfried Ltd. Kit comprising a packaging material and a solid pharmaceutical or nutraceutical product contained in the packaging material
JP6138798B2 (ja) 2011-09-16 2017-05-31 パーデュー ファーマ エルピー 不正改変抵抗性即時放出性製剤
MX355478B (es) 2011-09-16 2018-04-19 Purdue Pharma Lp Formulaciones farmacéuticas resistentes a la manipulación.
WO2013084059A1 (en) 2011-12-09 2013-06-13 Purdue Pharma L.P. Pharmaceutical dosage forms comprising poly (epsilon- caprolactone) and polyethylene oxide
BR112014019988A8 (pt) 2012-02-28 2017-07-11 Gruenenthal Gmbh Forma de dosagem resistente a socamento compreendendo um composto farmacologicamente ativo e um polímero aniônico
MX354677B (es) 2012-03-02 2018-03-15 Rhodes Pharmaceuticals Lp Formulaciones de liberacion inmediata resistentes a la manipulacion.
EP2844236B1 (en) 2012-04-17 2018-12-19 Purdue Pharma LP Systems and methods for treating an opioid-induced adverse pharmacodynamic response
ES2692944T3 (es) 2012-04-18 2018-12-05 Grünenthal GmbH Forma de dosificación farmacéutica resistente a la manipulación y resistente a la descarga rápida de la dosis
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
WO2014011830A1 (en) 2012-07-12 2014-01-16 Mallinckrodt Llc Extended release, abuse deterrent pharmaceutical compositions
US10316042B2 (en) 2012-07-16 2019-06-11 Rhodes Technologies Process for improved opioid synthesis
CN104507947B (zh) * 2012-07-16 2017-06-27 罗德科技公司 用于改进的阿片样物质合成的方法
ES2716574T3 (es) 2012-08-03 2019-06-13 Johnson Matthey Plc Un método de preparación de oxicodona
JP5922851B2 (ja) 2012-11-30 2016-05-24 アキュラ・ファーマシューティカルズ・インコーポレーテッド 活性医薬成分の自己制御放出
SG11201506064UA (en) 2013-02-05 2015-08-28 Purdue Pharma Lp Tamper resistant pharmaceutical formulations
US9770710B2 (en) 2013-02-20 2017-09-26 University Of Washington Through Its Center For Commercialization Hydrogenation and disproportionation catalysis
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
EP3003283A1 (en) 2013-05-29 2016-04-13 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
JP6445537B2 (ja) 2013-05-29 2018-12-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング １個または複数の粒子を含有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
JP6449871B2 (ja) 2013-07-12 2019-01-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング エチレン−酢酸ビニルポリマーを含有する改変防止剤形
GB201313211D0 (en) 2013-07-24 2013-09-04 Cambrex Karlskoga Ab New process
RU2637934C2 (ru) 2013-08-02 2017-12-08 Джонсон Мэтти Паблик Лимитед Компани Способ получения оксиморфона
GB201313915D0 (en) * 2013-08-02 2013-09-18 Johnson Matthey Plc Process
WO2015069717A1 (en) 2013-11-07 2015-05-14 Mallinckrodt Llc Production of 6-hydroxy morphinans without the isolation of intermediates
CA2929909C (en) 2013-11-13 2018-08-21 Euro-Celtique S.A. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
WO2015078891A1 (en) 2013-11-26 2015-06-04 Farmaceutici Formenti S.P.A. Preparation of a powdery pharmaceutical composition by means of cryo-milling
US10227354B2 (en) 2013-12-18 2019-03-12 Cody Laboratories, Inc. Conversion of oxycodone base to oxycodone hydrochloride
US8846923B1 (en) 2013-12-18 2014-09-30 Cody Laboratories, Inc. Preparation of 14-hydroxycodeinone sulfate
US9062062B1 (en) 2013-12-18 2015-06-23 Cody Laboratories, Inc. Synthesis of oxycodone hydrochloride
CA2937007C (en) 2014-01-15 2018-11-06 Rhodes Technologies Process for improved oxymorphone synthesis
US9932348B2 (en) 2014-01-15 2018-04-03 Rhodes Technologies Process for improved oxycodone synthesis
WO2015120201A1 (en) 2014-02-05 2015-08-13 Kashiv Pharma, Llc Abuse-resistant drug formulations with built-in overdose protection
AU2015237721B2 (en) 2014-03-26 2018-04-26 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release coated reservoir solid dosage form
WO2015173195A1 (en) 2014-05-12 2015-11-19 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
US9872835B2 (en) 2014-05-26 2018-01-23 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
EP3166948A1 (en) * 2014-07-09 2017-05-17 Rhodes Technologies Inc. Reduction of alpha, beta-unsaturated ketone levels in morphinan derivative compositions
CA2910865C (en) 2014-07-15 2016-11-29 Isa Odidi Compositions and methods for reducing overdose
US20160052932A1 (en) * 2014-08-25 2016-02-25 Johnson Matthey Public Limited Company Processes for Making Opioids Including 14-Hydroxycodeinone and 14-hydroxymorphinone
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
CN105777766B (zh) * 2014-12-15 2017-11-24 北大方正集团有限公司 Delta‑7溴甲纳曲酮的制备方法
US9918979B2 (en) * 2015-01-29 2018-03-20 Johnson Matthey Public Limited Company Process of preparing low ABUK oxymorphone hydrochloride
EP3285745A1 (en) 2015-04-24 2018-02-28 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
GB201513203D0 (en) 2015-07-27 2015-09-09 Cambrex Charles City Inc New process
WO2017040607A1 (en) 2015-08-31 2017-03-09 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
US10842750B2 (en) 2015-09-10 2020-11-24 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
US9861629B1 (en) 2015-10-07 2018-01-09 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
US20180104236A1 (en) 2016-09-26 2018-04-19 Euro-Celtique S. A. Methods of treatment comprising administering a high daily dose of oxycodone and naloxone in a 2:1 weight ratio
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
US10941154B2 (en) 2017-06-20 2021-03-09 Johnson Matthey Public Limited Company Hydrogenation process for preparing oxycodone hydrochloride from 14-hydroxycodeinone
KR20200022026A (ko) 2017-06-30 2020-03-02 퍼듀 퍼머 엘피 치료 방법 및 이의 약형
CN110330500B (zh) * 2019-07-12 2021-11-23 宜昌人福药业有限责任公司 一种6β-羟基-7,8-二氢-吗啡衍生物的立体选择性合成方法
CN113009060B (zh) * 2021-02-24 2022-10-21 西南药业股份有限公司 高效液相色谱法测定盐酸羟考酮含量的方法

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE286431C (enExample)
DE296916C (enExample) *
US1485673A (en) * 1924-03-04 Ministrator
US100000A (en) * 1870-02-22 Improved sun-bonnet for horses
US1468805A (en) 1923-09-25 Htabtin ereund
US105553A (en) 1870-07-19 Improvement in kettle for melting, mixing, and casting metals
US420098A (en) * 1890-01-28 Mowing-machine
US710223A (en) * 1901-06-10 1902-09-30 Thew Automatic Shovel Company Power-shovel.
SU64699A1 (ru) 1944-01-26 1944-11-30 А.И. Лютенберг Способ получени сол нокислого дигидрооксикодеинона
ES212554A1 (es) 1953-12-01 1954-08-16 Casanovas Albajes Cesar Un procedimiento para la obtención de un vidrio orgánico
US2772270A (en) 1954-10-21 1956-11-27 M J Lewenstein 14-hydroxymorphinone and 8, 14-dihydroxydihydromorphinone
US2806033A (en) 1955-08-03 1957-09-10 Lewenstein Morphine derivative
US3173878A (en) * 1960-02-26 1965-03-16 Ibm Process of making microcapsules
US3173876A (en) 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
NL271831A (enExample) 1960-11-29
US3276586A (en) 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
US3916898A (en) 1964-05-20 1975-11-04 Searle & Co Administration of medicaments and the like
NL6714885A (enExample) 1967-11-02 1969-05-06
US3541006A (en) * 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3905981A (en) * 1973-10-12 1975-09-16 Research Corp N-dealkylation of tertiary amines
US3894026A (en) 1973-10-16 1975-07-08 Merck & Co Inc Production of thebaine
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4063064A (en) 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US3984026A (en) * 1976-03-26 1976-10-05 Shoup Russel W Combined can opening and sealing device
US4045440A (en) 1976-09-16 1977-08-30 The United States Of America As Represented By The Department Of Health, Education And Welfare Method of producing thebaine from codeine and oripavine from morphine
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4285987A (en) 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4272540A (en) * 1979-04-24 1981-06-09 Sisa, Incorporated 14-Methoxymorphinan-6-one compounds and therapeutic methods of treating pain and drug dependence with them
US4370333A (en) * 1981-06-29 1983-01-25 Sisa, Incorporated 17-Cyclopropylmethyl-3-hydroxy-14-methoxy 7α-methyl-morphinan-6-one and therapeutic method of treating pain with it
US4795813A (en) * 1981-08-17 1989-01-03 The Florida Board Of Regents On Behalf Of The Florida State University Synthesis of derivatives of codeine and other 3-O-alkylmorphines
US4639520A (en) * 1984-03-27 1987-01-27 Mallinckrodt, Inc. Preparation of 14-hydroxy-N-ethoxy-carbonyl-norcodeinone
US5112975A (en) 1984-03-27 1992-05-12 Mallinckrodt Specialty Chemicals Company Preparation of noroxymorphone from morphine
US4861598A (en) 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4810699A (en) * 1987-02-20 1989-03-07 American Home Products Corporation Substituted 1,3,4,9-tetrahydropyrano[3,4,-b]indole-1-acetic acids, pharmaceutical compositions containing them, and methods for treating inflammatory conditions and for analgesic purposes using them
US4810669A (en) * 1987-07-07 1989-03-07 Oki Electric Industry Co., Ltd. Method of fabricating a semiconductor device
DE3812567A1 (de) 1988-04-15 1989-10-26 Basf Ag Verfahren zur herstellung pharmazeutischer mischungen
HU208633B (en) 1991-02-04 1993-12-28 Alkaloida Vegyeszeti Gyar Process for production of analgetic compositions as applicable for blocking of opioid-binding spaces /2-receptors/ causing respiration depression
US5215758A (en) 1991-09-11 1993-06-01 Euroceltique, S.A. Controlled release matrix suppository for pharmaceuticals
US5656295A (en) 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5472712A (en) 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5273760A (en) 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5286493A (en) 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5324351A (en) 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
JP3433871B2 (ja) * 1996-01-26 2003-08-04 株式会社デンソー 集積化半導体歪みセンサ及びその製造方法
PT1014941E (pt) 1996-06-26 2009-07-08 Univ Texas Formulação farmacêutica extrudível por termofusão
US5869669A (en) 1996-07-26 1999-02-09 Penick Corporation Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates
ES2121554B1 (es) * 1996-12-23 1999-06-16 Univ Santiago Compostela Procedimiento de obtencion de 14-hidroximofinonas mediante fotooxidac ion de alcaloides morfinicos con sistema alcoxidienico en el anillo c.
GB9713703D0 (en) 1997-06-30 1997-09-03 Johnson Matthey Plc Preparation of opiates
GB9717629D0 (en) 1997-08-21 1997-10-22 Johnson Matthey Plc Removal of residual organic solvents
US6710223B1 (en) * 1997-09-10 2004-03-23 The Procter & Gamble Company Method for improving skin condition
GB9805516D0 (en) 1998-03-17 1998-05-13 Johnson Matthey Plc Preparation of opiates
AU1426200A (en) * 1998-10-14 2000-05-01 Amic Ab A matrix and method of producing said matrix
US6177567B1 (en) * 1999-10-15 2001-01-23 Boehringer Ingelheim Chemicals, Inc. Method for preparing oxycodone
US6284769B1 (en) * 1999-12-03 2001-09-04 The Board Of Trustees Of The University Of Illinois Nonpeptide kappa opioid receptor antagonists
US6133132A (en) * 2000-01-20 2000-10-17 Advanced Micro Devices, Inc. Method for controlling transistor spacer width
SI1299104T1 (sl) * 2000-02-08 2009-10-31 Euro Celtique Sa Oralne formulacije opioidnih agonistov, varne pred zlorabo
US20030194748A1 (en) 2000-05-29 2003-10-16 Tohru Nagasaki Method for labeling with tritium
US7200357B2 (en) * 2000-10-20 2007-04-03 Universal Electronics Inc. Automotive storage and playback device and method for using the same
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
CN1514729B (zh) * 2001-06-05 2012-09-05 控制释放系统公司 缓释的止痛化合物
CA2449519A1 (en) 2001-06-08 2002-12-19 Endo Pharmaceuticals, Inc. Controlled release dosage forms using acrylic polymer, and process for making the same
AU2002316738B2 (en) 2001-07-18 2009-01-08 Euro-Celtique S.A. Pharmaceutical combinations of oxycodone and naloxone
US6845770B2 (en) * 2002-01-15 2005-01-25 Aerogen, Inc. Systems and methods for clearing aerosols from the effective anatomic dead space
ES2327034T3 (es) * 2002-03-26 2009-10-23 Euro-Celtique S.A. Composiciones recubiertas con gel de liberacion sostenida.
CA2483655A1 (en) * 2002-04-29 2003-11-13 Alza Corporation Methods and dosage forms for controlled delivery of oxycodone
US7702280B2 (en) * 2002-05-27 2010-04-20 Ntt Docomo, Inc. Mobile communication system, transmission station, reception station, relay station, communication path deciding method, and communication path deciding program
AU2003245345A1 (en) 2002-05-31 2003-12-19 Alza Corporation Dosage forms and compositions for osmotic delivery of variable dosages of oxycodone
CA2491572C (en) * 2002-07-05 2010-03-23 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opiods and other drugs
US20040058946A1 (en) * 2002-07-05 2004-03-25 Buchwald Stephen L. Abuse-resistant prodrugs of oxycodone and other pharmaceuticals
EP1537118A1 (en) * 2002-08-15 2005-06-08 Noramco, Inc. Oxycodone-hydrochloride polymorhs
WO2004045551A2 (en) 2002-11-15 2004-06-03 Branded Products For The Future Pharmaceutical composition
EP1575584A4 (en) * 2002-11-29 2006-02-01 Forest Laboratories METHOD FOR THE TREATMENT OF ACUTE CHARACTERIZATION BY UNIFORM FORMING WITH IBUPROFEN AND OXYCODON
FR2850576B1 (fr) * 2003-02-05 2007-03-23 Ethypharm Sa Composition comprenant un melange de principes actifs, et procede de preparation
ATE454169T1 (de) 2003-03-13 2010-01-15 Controlled Chemicals Inc Oxycodon- konjugate mit niedrigerem missbrauch- potential und ausgedehnter tätigkeitsdauer
US6864370B1 (en) * 2003-06-05 2005-03-08 Zhaiwei Lin Process for manufacturing oxycodone
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
WO2005098414A1 (en) * 2004-03-30 2005-10-20 Euro-Celtique S.A Methods for detecting 14-hydroxycodeinone and codeinone
TWI483944B (zh) * 2004-03-30 2015-05-11 Euro Celtique Sa 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
US20050226929A1 (en) 2004-04-12 2005-10-13 Jianbo Xie Controlled release opioid analgesic formulation
WO2006004672A1 (en) 2004-06-25 2006-01-12 Tessera, Inc. Components with posts and pads
GB0421149D0 (en) 2004-09-23 2004-10-27 Johnson Matthey Plc Preparation of oxycodone
HRP20090387T1 (hr) 2005-03-04 2009-08-31 Euro-Celtique S.A. Postupak reduciranja alfa, beta nezasićenih ketona u opioidnim sastavima
ATE493417T1 (de) 2005-06-16 2011-01-15 Mallinckrodt Inc Synthetische route zu 14-hydroxylopiaten über 1- halogenthebain oder analoga
CN101346384B (zh) 2005-11-22 2012-07-04 控制化学品公司 用于降低羟考酮和其它组分中杂质迈克尔受体水平的方法
US20070117826A1 (en) * 2005-11-23 2007-05-24 Forest Laboratories, Inc. Pharmaceutical formulations comprising ibuprofen, oxycodone, and 14-hydroxycodeinone
WO2007103105A2 (en) 2006-03-02 2007-09-13 Mallinckrodt Inc. Processes for preparing morphinan-6-one products with low levels of alpha, beta-unsaturated ketone compounds
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
ES2393221T3 (es) * 2006-12-04 2012-12-19 Noramco, Inc. Procedimiento de preparación de oxicodona con niveles reducidos de 14-hidroxicodeinona
WO2008070656A2 (en) 2006-12-04 2008-06-12 Noramco, Inc Process for reducing impurities in oxycodone base
GB2450691A (en) 2007-07-02 2009-01-07 Alpharma Aps One-pot preparation of oxycodone from thebaine
CA2804101C (en) 2010-07-02 2021-01-19 Johnson Matthey Public Limited Company Process for the synthesis and purification of oxycodone
US9062062B1 (en) * 2013-12-18 2015-06-23 Cody Laboratories, Inc. Synthesis of oxycodone hydrochloride

Also Published As

Publication number Publication date
ES2535618T3 (es) 2015-05-13
HRP20110425T4 (hr) 2020-11-27
JP2014139205A (ja) 2014-07-31
DK2305683T3 (en) 2015-04-07
ES2566363T3 (es) 2016-04-12
HRP20150358T1 (hr) 2015-05-08
US20230365578A1 (en) 2023-11-16
JP5118223B2 (ja) 2013-01-16
US10407434B2 (en) 2019-09-10
NZ549430A (en) 2010-05-28
DK2316837T3 (en) 2018-04-16
US20100152449A1 (en) 2010-06-17
PL1730151T5 (pl) 2023-09-18
FIU20070284U0 (fi) 2007-07-04
CN101812065A (zh) 2010-08-25
ES2362282T5 (es) 2021-06-24
KR20120106784A (ko) 2012-09-26
CR20110376A (es) 2011-09-19
RS54941B1 (sr) 2016-11-30
WO2005097801A1 (en) 2005-10-20
AU2005230826C1 (en) 2014-10-16
PT2426132E (pt) 2016-03-31
SI1730151T2 (sl) 2021-03-31
MA28492B1 (fr) 2007-03-01
US7674798B2 (en) 2010-03-09
JP2015187134A (ja) 2015-10-29
EP1730151B1 (en) 2011-03-09
AU2005230826A1 (en) 2005-10-20
US20070117829A1 (en) 2007-05-24
JP2018184462A (ja) 2018-11-22
KR20200000499A (ko) 2020-01-02
CY1117841T1 (el) 2017-05-17
SI2316837T1 (en) 2018-05-31
PL2319846T3 (pl) 2016-12-30
US20160175298A1 (en) 2016-06-23
KR20140021716A (ko) 2014-02-20
US20200087316A1 (en) 2020-03-19
US20060173029A1 (en) 2006-08-03
CY1116327T1 (el) 2017-02-08
US12060361B2 (en) 2024-08-13
EP2426132A1 (en) 2012-03-07
MY172063A (en) 2019-11-13
AU2009200335B2 (en) 2011-07-28
ME02482B (me) 2017-02-20
HRP20110425T1 (en) 2011-07-31
RS53891B1 (sr) 2015-08-31
US20210198268A1 (en) 2021-07-01
IL235298A (en) 2016-11-30
US20190161492A1 (en) 2019-05-30
AP2006003738A0 (en) 2006-10-31
HK1098745A1 (en) 2007-07-27
US20150265597A1 (en) 2015-09-24
KR20120046309A (ko) 2012-05-09
KR20180088505A (ko) 2018-08-03
ME02411B (me) 2016-09-20
EP2305683B2 (en) 2024-09-11
JP2007531756A (ja) 2007-11-08
LT2316837T (lt) 2018-04-10
IL241117A0 (en) 2015-11-30
MY143205A (en) 2011-03-31
US20210094963A1 (en) 2021-04-01
DE602005026786D1 (de) 2011-04-21
SG170735A1 (en) 2011-05-30
PT2305683E (pt) 2015-05-18
US20070179169A1 (en) 2007-08-02
EA200601520A1 (ru) 2007-02-27
US20090227615A1 (en) 2009-09-10
EP2319846A1 (en) 2011-05-11
IL214050A (en) 2013-09-30
ATE501150T1 (de) 2011-03-15
US20160251365A1 (en) 2016-09-01
US20160185790A1 (en) 2016-06-30
ES2665287T3 (es) 2018-04-25
CA2774121C (en) 2016-02-16
US20160250204A1 (en) 2016-09-01
ZA200607181B (en) 2007-11-28
PL2316837T3 (pl) 2018-07-31
US11384091B2 (en) 2022-07-12
US7674799B2 (en) 2010-03-09
IL213890A0 (en) 2011-07-31
US20160251364A1 (en) 2016-09-01
PL1730151T3 (pl) 2011-08-31
US10696684B2 (en) 2020-06-30
RS51693B2 (sr) 2021-02-26
HUE029913T2 (en) 2017-04-28
DK1730151T3 (da) 2011-06-20
KR20090104145A (ko) 2009-10-05
CN1960994B (zh) 2012-09-05
US20070117831A1 (en) 2007-05-24
HUE036451T2 (hu) 2018-07-30
IL213890A (en) 2015-10-29
PT1730151E (pt) 2011-06-01
HRP20180407T1 (hr) 2018-04-20
SI1730151T1 (sl) 2011-06-30
HK1155728A1 (en) 2012-05-25
AU2005230826B2 (en) 2008-11-06
US20160185788A1 (en) 2016-06-30
US20180022754A1 (en) 2018-01-25
RS57000B1 (sr) 2018-05-31
KR20100069719A (ko) 2010-06-24
BRPI0508758B1 (pt) 2018-10-09
AT9952U1 (de) 2008-06-15
CR8593A (es) 2007-07-19
NO337669B1 (no) 2016-05-30
CN1960994A (zh) 2007-05-09
US20160185789A1 (en) 2016-06-30
DK200700214U3 (da) 2008-02-08
CA2774121A1 (en) 2005-10-20
FI7843U1 (fi) 2008-04-28
MX2020008878A (es) 2020-11-09
ES2938727T3 (es) 2023-04-14
CA2913355C (en) 2021-04-20
ECSP066953A (es) 2006-12-20
JP2011157370A (ja) 2011-08-18
EP2316837A1 (en) 2011-05-04
US20050222188A1 (en) 2005-10-06
BRPI0508758B8 (pt) 2021-05-25
IL213891A0 (en) 2011-07-31
US20160175299A1 (en) 2016-06-23
EP1730151A4 (en) 2007-05-23
US10259819B2 (en) 2019-04-16
CN102838607A (zh) 2012-12-26
TW200540177A (en) 2005-12-16
US20160250205A1 (en) 2016-09-01
PT2319846T (pt) 2016-08-12
DK1730151T4 (da) 2020-10-19
CN102127086A (zh) 2011-07-20
US9073933B2 (en) 2015-07-07
ES2362282T3 (es) 2011-06-30
EP2305683B8 (en) 2015-03-04
EP2314589A1 (en) 2011-04-27
US10689389B2 (en) 2020-06-23
SI2319846T1 (sl) 2016-08-31
CN101812065B (zh) 2012-03-28
PL2426132T3 (pl) 2016-06-30
JP5378486B2 (ja) 2013-12-25
US9777011B2 (en) 2017-10-03
TW201231469A (en) 2012-08-01
IL213888A0 (en) 2011-07-31
US20160264588A1 (en) 2016-09-15
NZ601326A (en) 2013-10-25
EP2305683B1 (en) 2015-01-28
US20160176888A1 (en) 2016-06-23
PL2305683T3 (pl) 2015-07-31
US7683072B2 (en) 2010-03-23
BRPI0508758A (pt) 2007-08-28
US7674800B2 (en) 2010-03-09
JP2017125052A (ja) 2017-07-20
EP2426132B1 (en) 2016-01-13
KR20150046393A (ko) 2015-04-29
US20070117830A1 (en) 2007-05-24
NO20064935L (no) 2006-12-18
EP1730151B2 (en) 2020-09-16
DK2319846T3 (en) 2016-08-15
RS54598B1 (sr) 2016-08-31
SI2426132T1 (sl) 2016-04-29
US20160251363A1 (en) 2016-09-01
SI2305683T1 (sl) 2015-04-30
CA2913355A1 (en) 2005-10-20
AP2232A (en) 2011-05-04
CN102127086B (zh) 2013-11-27
KR20140133615A (ko) 2014-11-19
EP2311839A1 (en) 2011-04-20
NZ602862A (en) 2014-01-31
US11236098B2 (en) 2022-02-01
MY154985A (en) 2015-08-28
KR20070022033A (ko) 2007-02-23
LT2314589T (lt) 2023-06-12
RS51693B (sr) 2011-10-31
EP2305683A1 (en) 2011-04-06
SG170736A1 (en) 2011-05-30
US20230159548A1 (en) 2023-05-25
EA013208B1 (ru) 2010-04-30
US20130005977A1 (en) 2013-01-03
IL178038A0 (en) 2006-12-31
DE202005021371U1 (de) 2007-10-25
IL213889A (en) 2012-06-28
US20200062772A1 (en) 2020-02-27
TWI365880B (en) 2012-06-11
EP2319846B1 (en) 2016-05-04
DK2426132T3 (en) 2016-04-04
KR100993911B1 (ko) 2010-11-11
US20110207762A1 (en) 2011-08-25
TWI483944B (zh) 2015-05-11
HK1155729A1 (en) 2012-05-25
KR101410141B1 (ko) 2014-06-25
CN102887903B (zh) 2016-01-27
HRP20160885T1 (hr) 2016-09-23
HRP20160223T1 (hr) 2016-03-25
EP2316837B1 (en) 2018-01-10
PT2316837T (pt) 2018-04-02
ME03068B (me) 2019-01-20
CA2557845A1 (en) 2005-10-20
KR20130020962A (ko) 2013-03-04
EP1730151A1 (en) 2006-12-13
CA2557845C (en) 2013-10-01
DK200700214U1 (da) 2007-11-23
KR100930730B1 (ko) 2009-12-09
US20160175300A1 (en) 2016-06-23
ME01299B (me) 2011-10-31
US7129248B2 (en) 2006-10-31
JP6503392B2 (ja) 2019-04-17
US9522919B2 (en) 2016-12-20
AU2009200335A1 (en) 2009-02-26
IL214050A0 (en) 2011-08-31
ES2585576T3 (es) 2016-10-06
US20160176889A1 (en) 2016-06-23
JP4912294B2 (ja) 2012-04-11
US20150258086A1 (en) 2015-09-17
AR049012A1 (es) 2006-06-21
CY1111487T1 (el) 2015-08-05
CY1117228T1 (el) 2017-04-05
CY1120171T1 (el) 2018-12-12
IL178038A (en) 2015-10-29
IL241117B (en) 2020-06-30
JP2012188439A (ja) 2012-10-04
US8822687B2 (en) 2014-09-02
KR20110110377A (ko) 2011-10-06
KR101200700B1 (ko) 2012-11-13
IL213889A0 (en) 2011-07-31
TW201509943A (zh) 2015-03-16
SG10201406658VA (en) 2014-12-30
CN102887903A (zh) 2013-01-23
CN102838607B (zh) 2016-08-03
MX363228B (es) 2019-03-15
US20150265598A1 (en) 2015-09-24
EP2314589B1 (en) 2022-12-28
HUE028233T2 (en) 2016-12-28
JP2012072162A (ja) 2012-04-12
JP5543991B2 (ja) 2014-07-09

Similar Documents

Publication Publication Date Title
PE20050880A1 (es) Proceso para reducir la cantidad de 14-hidroxicodeinona en una preparacion de clorhidrato de oxicodona
TW200710081A (en) Process for producing carboxylic acid
UY30475A1 (es) Procedimientos para fabricar bromuro de 3(r)-(2-hidroxi-2,2-dietien-2-ilaxetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo[2.2.2]octano.
AR047319A1 (es) Proceso para remocion de impurezas de licor madre en la sintesis de acido carboxilico que utiliza filtracion por presion
CO6670555A2 (es) Método para recuperar oro por extracción con solvente
BRPI0401876A (pt) Processo para recuperação de catalisador de metal de um licor mãe, corrente de impurezas orgânicas com alto ponto de ebulição, corrente rica em solvente, processo para produção de uma corrente de licor mãe superconcentrado, e, composição
JP2006291352A5 (enExample)
RU2012137266A (ru) Способ получения водного потока при получении эталона
BRPI0508383A (pt) remoção de compostos redutores de permanganato da corrente do processo de carbonilação de metanol
RU2010133160A (ru) Способ синтеза тетрагидробиоптерина
BR112012028507A2 (pt) processo para recuperação de etanol com extrações laterais para regular as concentrações de c3 + alcoóis
GB2437006A (en) Salts assisted selective extraction of 6-acetyl-4.1',6'trichlorogalactosucrose and 4,1',6'trichlorogalactosucrose from aqueous reaction mixture
DE602005000334D1 (de) Verfahren zur herstellung von oxycodon
MX2010005124A (es) Procedimiento de preparacion de compuestos morfinicos.
EA200970644A1 (ru) Способ и устройство для извлечения металла и отделения мышьяка от мышьяксодержащего раствора
EA201190206A1 (ru) Устройство и способ удаления примесей в связи с жидкостной экстракцией меди
PE20050001A1 (es) Metodo y equipo para purificar una solucion de extraccion de un arrastre acuoso e impurezas
CO6170353A2 (es) Metodo y aparato para remover arsenico de una solucion
TW200510571A (en) High purity copper sulfate and method for production thereof
JP4552941B2 (ja) アニリンの精製方法および製造方法
ES2189764T3 (es) Proceso para la separacion y purificacion de una mezcla acuosa que tiene como componentes principales acido acetico y acido formico.
BRPI0411925A (pt) processo para separação e recuperação de ácido 3-hidroxipropiÈnico e ácido acrìlico
RU2005109425A (ru) Способ экстракции растворителем
CN1123825A (zh) 一种石油馏分油氨醇脱酸工艺
TW200600464A (en) Method for recovering highly pure oxalic acid aqueous solution

Legal Events

Date Code Title Description
FG Grant, registration